Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash & Equivalents (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Cash & Equivalents for 16 consecutive years, with $27.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 71.19% to $27.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $27.2 million, a 71.19% increase, with the full-year FY2024 number at $8.3 million, down 75.35% from a year prior.
  • Cash & Equivalents was $27.2 million for Q3 2025 at Gyre Therapeutics, down from $28.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $75.4 million in Q2 2022 to a low of $2.2 million in Q3 2023.
  • A 5-year average of $27.4 million and a median of $23.1 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 90.85% in 2023, then soared 622.73% in 2024.
  • Gyre Therapeutics' Cash & Equivalents stood at $44.3 million in 2021, then tumbled by 51.14% to $21.7 million in 2022, then surged by 54.66% to $33.5 million in 2023, then tumbled by 75.35% to $8.3 million in 2024, then skyrocketed by 229.5% to $27.2 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Cash & Equivalents are $27.2 million (Q3 2025), $28.6 million (Q2 2025), and $8.3 million (Q4 2024).